Anti-thyroid peroxidase antibodies are associated with the absence of distant metastases in patients with newly diagnosed breast cancer

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 4, 2012, Pages 709-714

  Farahati, Jamshid ^a   Roggenbuck, Dirk ^b   Gilman, Elena ^a   Schtte, Martin ^c   Jagminaite, Elena ^a   Seyed Zakavi, Rasoul ^a   Lning, Thomas ^d   Heissen, Eberhard ^a  

^a Nuclear Medicine and Radiotherapy   (Germany)

^b Medipan GmbH   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d Albertinen Pathology Hamburg   (Germany)

Author keywords

breast cancer; prognosis; thyroid; thyroid peroxidase antibody

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; TUMOR ANTIGEN;

ADULT; ARTICLE; BLOOD ANALYSIS; BREAST CANCER; CANCER GRADING; DIAGNOSTIC VALUE; DISTANT METASTASIS; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR CLASSIFICATION; TUMOR VOLUME;

ANTIBODIES, NEOPLASM; BREAST NEOPLASMS; HUMANS; IODIDE PEROXIDASE; MIDDLE AGED; NEOPLASM METASTASIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860495582     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm.2011.819     Document Type: Article

References (44)

1. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896;ii:104-7.
2. Brinton LA, Hoffman DA, Hoover R, Fraumeni JF. Relationship of thyroid disease and use of thyroid supplements to breast cancer risk. J Chron Dis 1984;37:877-93. (Pubitemid 15153987)
3. Franceschi S, la Vecchia C, Negri E, Parazzini F, Boyle P. Breast cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer 1990;26:781-5. (Pubitemid 20328547)
4. Altieri A, Tavani A, Gallus S, Bosetti C, Talamini R, Franceschi S, et al Do thyroid disorders increase the risk of breast cancer ? Cancer Epidemiol Biomarkers Prev 2002;12:684-6.
5. Mittra I, Perrin J, Kumaoka S. Thyroid and other autoantibodies in British and Japanese women: an epidemiological study of breast cancer. Br Med J 1976;1:257-9.
6. Ito K, Maruchi N. Breast cancer in patients with Hashimoto's thyroiditis. Lancet 1975;ii:1119-21.
7. Kapdi JJ, Wolfe JN. Breast cancer relationship to thyroid supplements for hypothyroidism. J Am Med Assoc 1976;236: 1124-7.
8. Rasmusson B, Feldt-Rasmussen U, Heged ü s L, Perrild H, Bech K, H ø ier-Madsen M. Thyroid function in patients with breast cancer. J Cancer Clin Oncol 1987;23:553-6. (Pubitemid 17057387)
9. Mittra I, Haysward JL. Hypothalamic-pituitary-thyroid axis in breast cancer. Lancet 1974;i:885-8.
10. Shering SG, Zbar AP, Moriatry M. Thyroid disorders and breast cancer. Eur J Cancer Prev 1996;5:504-6. (Pubitemid 27087376)
11. Maruchi N, Annegers JF, Kurland LT. Hashimoto's thyroiditis and breast cancer. Mayo Clin Proc 1976;51:263-5.
12. Lemmarie M, Baugnet-Mahieu L. Thyroid function in women with breast cancer. Eur J Cancer Clin Oncol 1986;22: 301-7. (Pubitemid 16127868)
13. Moossa AR, Price-Evans DA, Brewer AC. Thyroid status and breast cancer: reappraisal of an old relationship. Ann R Coll Surg 1973;53:178-88.
14. Kurland LT, Annegers JF. Breast cancer and Hashimoto's thyroiditis [letter]. Lancet 1976;1:808.
15. Anker GB, L ø nning PE, Aakvaag A, Lien EA. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scan J Clin Lab Invest 1998;58:103-7. (Pubitemid 28185378)
16. Zophel K, Roggenbuck D, Schott M. Clinical review about TRAb assay's history. Autoimmun Rev 2010;9:695-700.
17. McLachlan SM, Rapoport B. The molecular biology of thyroid peroxidase: cloning, expression, and role as autoantigen in autoimmune thyroid disease. Endocr Rev 1992;13: 192-206.
18. Khoury EL, Hammond L, Bottazzo GF, Doniach D. Presence of the organ specifi c "microsomal" autoantigen on the surface of human thyroid cells in culture: its involvement in complement mediated cytotoxicity. Clin Exp Immunol 1981;45: 316-28. (Pubitemid 11079071)
19. Rapoport B, McLachlan SM. Thyroid autoimmunity. J Clin Invest 2001;108:1253-9. (Pubitemid 33107748)
20. Zophel K, Saller B, Wunderlich G, Gruning T, Koch R, Wilde J, et al. Autoantibodies to thyroperoxidase (TPO antibody) in a large population of euthyroid subjects: implications for the defi nition of TPO antibody reference intervals. Clin Lab 2003;49:591-600. (Pubitemid 37493457)
21. Gogas J, Kouskos E, Tseleni-Balafouta S, Markopoulos C, Revenas K, Gogas G, et al. Autoimmune thyroid disease in women with breast carinoma. Eur J Surg Oncol 2001;27: 626-30. (Pubitemid 33062168)
22. Myhil J, Reeve T, Hales IB. Thyroid function in breast cancer. Acta Endocrinol 1966;51:290-300.
23. Giani C, Fierabracci P, Bonnaci R, Gigliotti A, Compani D, De Negri F, et al. Relationship between breast cancer and thyroid disease: relevance of autoimmune thyroid disorders in breast malignancy. J Endocr Metab 1996;81:990-4. (Pubitemid 26083958)
24. Smyth PP. Autoimmune thyroid disease and breast cancer: a chance association. J Endocrinol Invest 2000;23:42-3. (Pubitemid 30105319)
25. Sarlis NJ, Gourgiotis L, Pucino F, Tolis GJ. Lack of association between Hashimoto thyroiditis and breast cancer: a quantitative research synthesis. Hormones 2002;1:35-41.
26. Simon MS, Tang MT, Bernstein L, Norman SA, Weiss L, Burkman RT, et al. Do thyroid disorders increase the risk of breast cancer ? Cancer Epidemiol Biomarkers Prev 2002;11:1574-8. (Pubitemid 36020009)
27. Riethdorf S, Hoegel B, John B, Ott G, Fritz P, Thon S, et al. Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplifi cation in specimens from adjuvant and metastatic breast cancer patients. J Cancer Res Clin Oncol 2011;137:261-9.
28. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007;18:1927-34. (Pubitemid 350286227)
29. Findeisen R, Albrecht S, Richter B, Deutschmann K, Distler W. Comparison of tissue polypeptide antigen (TPA) with cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in follow-up of breast cancer. Clin Chem Lab Med 1998;36: 841-6. (Pubitemid 28552125)
30. Smyth PP, Shering SG, Kilbane MT, Murray MJ, McDermott EW, Smith DF, et al. Serum thyroid peroxidase autoantibodies, thyroid volume and outcome in breast cancer. Clin Endocr Metab 1998;83:2711-6. (Pubitemid 28493765)
31. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 2005;103:1122-8.
32. Spitzweg C, Joba W, Eisenmenger W, Heufelder AE. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland and gastric mucosa. J Clin Endocrinol Metab 1998;83:1746-51. (Pubitemid 28501052)
33. Kilbane MT, Ajjan RA, Weetman AP, Dwyer R, McDermott EW, O'Higgins NJ, et al. Tissue iodine content and serum-mediated 125I uptake-blocking activity in breast cancer. J Clin Endocrinol Metab 2000;85:1245-50. (Pubitemid 32269380)
34. Ambroziak M, Pachucki J, Stachlewska-Nasfeter E, Nauman J, Nauman A. Disturbed expression of type 1 and type 2 iodothyronine deiodinase as well as titf1/nkx2-1 and pax-8 transcription factor genes in papillary thyroid cancer. Thyroid 2005;15: 1137-46. (Pubitemid 41720720)
35. Arnaldi LA, Borra RC, Maciel RM, Cerutti JM. Gene expression profi les reveal that DCN, DIO1, and DIO2 are underexpressed in benign and malignant thyroid tumors. Thyroid 2005;15: 210-21. (Pubitemid 40418688)
36. de Souza Meyer EL, Dora JM, Wagner MS, Maia AL. Decreased type 1 iodothyronine deiodinase expression might be an early and discrete event in thyroid cell dedifferentation towards papillary carcinoma. Clin Endocrinol 2005;62:672-8. (Pubitemid 40825936)
37. Schreck R, Schnieders F, Schmutzler C, Köhrle J. Retinoids stimulate type I iodothyronine 5′ -deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab 1994;79:791-8.
38. Pachucki J, Ambroziak M, Tanski Z, Luczak J, Nauman J, Nauman A. Type 1 5′ -iodothyronine deiodinase activity and mRNA are remarkably reduced in renal clear cell carcinoma. J Endocrinol Invest 2001;24:253-61. (Pubitemid 32435505)
39. Wawrzynska L, Sakowicz A, Rudzinski P, Langfort R, Kurzyna M. The conversion of thyroxine to triiodothyronine in the lung: comparison of activity of type I iodothyronine 5′ deiodinase in lung cancer with peripheral lung tissues. Monaldi Arch Chest Dis 2003;59:140-5. (Pubitemid 37420132)
40. Debski MG, Pachucki J, Ambroziak M, Olszewski W, Bar- Andziak E. Human breast cancer tissue expresses high level of type 1 5′ -deiodinase. Thyroid 2007;17:3-10. (Pubitemid 46214716)
41. Garc í a-Sol í s P, Aceves C. 5′ Deiodinase in two breast cancer cell lines: effect of triiodothyronine, isoproterenol and retinoids. Mol Cell Endocrinol 2003;201:25-31. (Pubitemid 36434278)
42. Conde I, Paniagua R, Zamora J, Blánquez MJ, Fraile B, Ruiz A, et al. Infl uence of thyroid hormone receptors on breast cancer cell proliferation. Ann Oncol 2003;17:60-4.
43. Silva JM, Dominguez G, González-Sancho JM, Garc í a JM, Silva J, Garc í a-Andrade C, et al. Expression of thyroid hormone receptor/erb A genes is altered in human breast cancer. Oncogene 2002;21:4307-16. (Pubitemid 34753837)
44. Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev 1998;18:404-33. (Pubitemid 27246883)